IMMUNOHISTOCHEMICAL EXPRESSION OF BCL2 AND ITS ASSOCIATION WITH OTHER PROGNOSTIC MARKERS IN INVASIVE CARCINOMA OF BREAST, NO SPECIAL TYPE IN TERTIARY CARE HOSPITAL
DOI:
https://doi.org/10.55519/JAMC-S4-13794Abstract
Background: B-cell lymphoma 2 (BCL2) is expressed by different malignancies including invasive breast carcinoma, No specific type. In breast carcinoma, its immunoexpression is associated with the grade of the tumor and other prognostic factors like Estrogen Receptors (ER), Progesterone Receptors (PR), Her 2, ki 67 and molecular subtypes. The objective was to determine the association of BCL2 immunoexpression with variable prognostic factors of invasive breast carcinoma. Methods: Over-all 71 cases of invasive breast carcinoma, no special type was included and BCL2 expression was evaluated along its association in terms of frequency with hormone receptors (ER, PR) Her2, ki 67 and grade of tumor. The expression of bcl2 was also further evaluated among molecular subtypes of breast carcinoma including luminal A, luminal B, Her 2 enriched and basal like (triple negative). Results: Positive Bcl2 expression was noted in 61% of cases of luminal A & B subtypes (hormone responsive tumors) pointing for its significant correlation with them while its relation with grade of the tumor, proliferation index and Her 2 status was found insignificant. Conclusion: Expression of BCL2 in invasive breast carcinoma, no special type is considered as a favorable prognostic marker irrespective of its histological grade and proliferation index
References
1. Lei S, Zheng R, Zhang S, Chen R, Wang S, Sun K, et al. Breast cancer incidence and mortality in women in China: temporal trends and projections to 2030. Cancer Biol Med [Internet]. 2021;18(3):900–9. Available from:http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0523
2. Knight T, Luedtke D, Edwards H, Taub JW, Ge Y. A delicate balance – The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics. Biochem Pharmacol [Internet]. 2019;162:250–61. Available from:http://dx.doi.org/10.1016/j.bcp.2019.01.015.
3. Warren CF, Wong-Brown MW, Bowden NA. BCL-2 family isoforms in apoptosis and cancer. Cell death & disease. 2019 Feb 21;10(3):177.https://doi.org/10.1038/s41419-019-1407-6
4. Um H-D. Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: a review focusing on mitochondrial respiration and reactive oxygen species. Oncotarget [Internet].2016;7(5):5193–203. Available from:http://dx.doi.org/10.18632/oncotarget.6405
5. Abu Siyam A, Demian S, Ahmed A, Ahmad M, Mersal B. B cell lymphoma-2 (bcl-2) in serum increased with breast cancer in Egyptian women. Journal of Bioscience and Applied Research [Internet]. 2018;4(3):296–305. Available from: http://dx.doi.org/10.21608/jbaar.2018.155808
6. 6. Hwang K-T, Han W, Kim J, Moon H-G, Oh S, Song YS, et al. Prognostic influence of BCL2 on molecular subtypes of breast cancer. J Breast Cancer [Internet]. 2017;20(1):54. Available from: http://dx.doi.org/10.4048/jbc.2017.20.1.54
7. Kawiak A, Kostecka A. Regulation of Bcl-2 Family Proteins in Estrogen Receptor-Positive Breast Cancer and Their Implications in Endocrine Therapy. Cancers. 2022 Jan;14(2):279.https://doi.org/10.3390/cancers14020279
8. Senichkin VV, Pervushin NV, Zuev AP, Zhivotovsky B, Kopeina GS. Targeting bcl-2 family proteins: What, where, when? Biochemistry (Mosc) [Internet]. 2020;85(10):1210–26. Available from: http://dx.doi.org/10.1134/s0006297920100090
9. Alizadeh M, Ghojazadeh M, Piri R, Mirza-Aghazadeh-Attari M, Mohammadi S, Naghavi-Behzad M. Age at diagnosis of breastJ Ayub Med Coll Abbottabad 2024;36(4 Suppl 1) 712cancer in Iran: A systematic review and meta-analysis. Iran JPublic Health [Internet]. 2021; Available from:http://dx.doi.org/10.18502/ijph.v50i8.6802
10. Kang SY, Lee SB, Kim YS, Kim Z, Kim HY, Kim HJ, et al. Breast cancer statistics in Korea, 2018. J Breast Cancer [Internet]. 2021;24(2):123. Available from:http://dx.doi.org/10.4048/jbc.2021.24.e22
11. Salvatorelli L, Puzzo L, Vecchio GM, Caltabiano R, Virzì V, Magro G. Ductal carcinoma in situ of the breast: An update with emphasis on radiological and morphological features as predictive prognostic factors. Cancers (Basel) [Internet]. 2020;12(3):609. Available from:http://dx.doi.org/10.3390/cancers12030609
12. Ahmed ST, Ahmed AM, Musa DH, Sulayvani FK, Al-Khyatt M, Pity IS. Proliferative index (Ki67) for prediction in breast duct carcinomas. Asian Pac J Cancer Prev [Internet]. 2018;19(4):955–9. Available from: http://dx.doi.org/10.22034/APJCP.2018.19.4.955
13. Acheampong T, Kehm RD, Terry MB, Argov EL, Tehranifar P. Incidence trends of breast cancer molecular subtypes by age and race/ethnicity in the US from 2010 to 2016. JAMA Netw Open [Internet]. 2020;3(8):e2013226. Available from: http://dx.doi.org/10.1001/jamanetworkopen.2020.13226
14. Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review. Cancers (Basel) [Internet].2021;13(17):4287. Available from: http://dx.doi.org/10.3390/cancers13174287
15. 15. Pandit P, Patil R, Palwe V, Gandhe S, Patil R, Nagarkar R. Prevalence of molecular subtypes of breast cancer: a single
16. institutional experience of 2062 patients. European journal of breast health. 2020 Jan;16(1):39.. doi: 10.5152/ejbh.2019.4997
17. 16. Pandey P, Bhake A. Bcl-2 immunoexpression in invasive Ductal carcinoma and its evaluative correlation with molecular subtypes and BR-Grade and TNM stage. In: Breast Cancer Updates. IntechOpen; 2023.
18. 17. Sharmila G , Praba V . BCL2 expression in ductal carcinoma of breast and its association with other clinicopathologic variables.
19. IP Arch Cytol Histopathology Res 2020;5(1):75-80.https://doi.org/10.18231/j.achr.2020.015
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Nadia Purnama Dewi, Wafda Azizah, Rika Amran, Dessy Abdullah, Rifkind Malik, Ade Teti Vani
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
